Show simple item record

Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase

dc.contributor.authorEskazan, Ahmet Emre
dc.date.accessioned2021-03-03T10:51:15Z
dc.date.available2021-03-03T10:51:15Z
dc.date.issued2017
dc.identifier.citationEskazan A. E. , "Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase", EXPERT OPINION ON PHARMACOTHERAPY, cilt.18, sa.3, ss.325-326, 2017
dc.identifier.issn1465-6566
dc.identifier.othervv_1032021
dc.identifier.otherav_24facf6b-68dd-4c93-8b0f-b5433072f234
dc.identifier.urihttp://hdl.handle.net/20.500.12627/29738
dc.identifier.urihttps://doi.org/10.1080/14656566.2017.1282697
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectTemel Eczacılık Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleUpfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase
dc.typeMakale
dc.relation.journalEXPERT OPINION ON PHARMACOTHERAPY
dc.contributor.departmentİstanbul Üniversitesi , Açık ve Uzaktan Eğitim Fakültesi , Coğrafya
dc.identifier.volume18
dc.identifier.issue3
dc.identifier.startpage325
dc.identifier.endpage326
dc.contributor.firstauthorID238399


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record